Table 3

 Summary of clinical responses at week 16

Clinical end pointInfliximab(n = 13)Etanercept(n = 14)
ACR20, American College of Rheumatology 20% improvement; ACR50, American College of Rheumatology 50% improvement; DAS28, Disease Activity Score based on 28 joints; HAQ, Health Assessment Questionnaire.
ACR20
    n (%)8 (61.5%)4 (28.6%)
ACR50
    n (%)4 (30.7%)2 (14.3%)
DAS28
    Mean (SD)4.0 (1.5)5.2 (1.6)
    % change from baseline−30.8 (28.6)−16.0 (24.2)
Patients with DAS28 score <2.6
    n (%)2 (15.4%)1 (7.1%)
Patients with HAQ decrease >0.22
    n (%)8 (61.5%)2 (14.3%)
Patients with HAQ decrease >0.40
    n (%)5 (38.5%)0 (0.0%)